BTK (E41K), active Human Recombinant Kinase Protein
10 µg of active BTK (E41K). N-terminal 6His-tagged recombinant, human full length BTK.
No items found.
Biological information
Background
N-terminal 6His-tagged recombinant, human full length BTK. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked aγglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460).
Target class
Kinase
Family
TK
Accession number
NM_000061
Target Name
BTK (E41K), active Human Recombinant Kinase Protein
Target Alias
BTK, ATK, BPK, AGMX1
Origin
Human
Theori. MW
78.4 kDa
Affinity tag
6His
Product specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Refer to CoA for Purity
Purification method
Ni2+/NTA-agarose
Sample Buffer
Specified activity
Refer to CoA
Application
For Research Only
Storage conditions
6 months at -70°C
Usage disclaimer
For Research Only
Chemical data
Background
N-terminal 6His-tagged recombinant, human full length BTK. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked aγglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460).
Compound name
Kinase
Catalog number
14-773
Molecular formula
CAS
MW
Ka
Percent composition
Product specifications
Physical state
Purity (HPLC 214nm)
Retention time (RP18 HPLC)
CMC
Exact mass
Stability
For Research Only
Solubility structure
Kinase Activity Assay Biological information
Background
N-terminal 6His-tagged recombinant, human full length BTK. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked aγglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460).
Target class
Kinase
Family
TK
Subfamily
Protein Name
BTK
Protein Alias
BTK, ATK, BPK, AGMX1
Accession Number
NM_000061
UniProt Number
Gene Name
Gene ID
Gene Aliases
Target Species
Human
Kinase Activity Assay Usage
Product Type
Application
Storage Conditions
6 months at -70°C
Usage disclaimer
Kinase Activity Assay Information
Assay Type
Assay Measures
Biological Information
Background
N-terminal 6His-tagged recombinant, human full length BTK. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked aγglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460).
Target class
Kinase
Family
TK
Accession Number
NM_000061
Target Name
BTK
Target Alias
BTK, ATK, BPK, AGMX1
Origin
Human
Theoretical MW
Affinity Tag
6His
Product Specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Refer to CoA for Purity
Purification method
Ni2+/NTA-agarose
Sample Buffer
Specified activity
Refer to CoA
Application
Storage conditions
6 months at -70°C
Usage disclaimer
For Research Only
Biological Information
Background
N-terminal 6His-tagged recombinant, human full length BTK. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked aγglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460).
Target class
Kinase
Family
TK
Accession Number
NM_000061
Target Name
BTK
Target Alias
BTK, ATK, BPK, AGMX1
Origin
Human
Theoretical MW
Affinity Tag
6His
Product Specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Refer to CoA for Purity
Purification method
Ni2+/NTA-agarose
Sample Buffer
Specified activity
Refer to CoA
Application
Storage conditions
6 months at -70°C
Usage disclaimer
For Research Only